Trial Profile
Open, noncomparative trial of multidrug regimens containing azithromycin and rifabutin administered three times per week for the treatment of M.[mycobacterium] avium complex (MAC) lung disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 May 2017
Price :
$35
*
At a glance
- Drugs Azithromycin (Primary) ; Rifabutin (Primary) ; Ethambutol
- Indications Mycobacterium avium complex infections
- Focus Therapeutic Use
- 18 May 2017 Status changed from active, no longer recruiting to completed.
- 16 Feb 2008 New trial record.